Shots:

• Click to receive $500M as up front- funding for research and development activities- clinical- regulatory & commercial milestones along with royalties on sales of CT-155 globally- will lead research and development activities and support Boehringer Ingelheim in global commercialization activities
• The companies will join their expertise to develop the mobile application- CT-155- which combines multiple clinically validated therapeutic interventions to help schizophrenia patients- modifying their behavior to achieve positive clinical outcomes alone or in combination with pharmaceutical therapies
• The collaboration will utilize cognitive and neurobehavioral mechanisms delivered through Click’s platform with the goal of reducing cognitive deficits and impaired social functioning in patients with schizophrenia

­ Ref: Businesswire | Image: StraitTimes